NCT Number: NCT00049751
Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis
The purpose of the study is to evaluate safety by collecting serious adverse events in subjects with moderately to severely active rheumatoid arthritis who are unable to obtain etanercept and who have failed one or more prior disease-modifying antirheumatic drugs (DMARDs).
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Thomas McGee, MD, Mobile, Alabama, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion:
- Subjects must meet ACR criteria for diagnosis of RA for at least 3 months, must meet ACR Functional Class I, II or III (1992 criteria) and must have a confirmed diagnosis of active moderate to severe rheumatoid arthritis as defined by 6 or more swollen joints and 9 or more tender joints;
- must also have DAS of 3.2 or greater at study entry,
- normal laboratory parameters and ESR >20,
- satisfactory response or intolerance to one or more prior DMARDs and
- be willing and able to give informed consent.
Exclusion:
- Previous treatment with total lymphoid irradiation or anti-CD4 or CAMPATH 1H monoclonal antibodies resulting in persistent CD4 lymphopenia,
- history of acute inflammatory joint disease other than RA,
- prior treatment with cyclophosphamide or chlorambucil,
- prior treatment with intravenous immunoglobulin within 70 days,
- history of malignant lymphoma,
- history of uncontrolled diabetes,
- unstable ischemic heart disease,
- active inflammatory bowel disease,
- active peptic ulcer disease or stroke,
- positive HIV status,
- positive serology for Hepatitis B or C,
- no previous history of tuberculosis or listeria infection,
- no previous history of cancer other than successfully treated skin cancer;
- women can not be pregnant or be breastfeeding
Treatment and study plan
Primary outcomes
-
Change in disease activity score at visit week 12 as compared to baseline
Sponsors and collaborators
Lead sponsor
Abbott
Industry
Registry information
Official study title
A Multicenter Study of the Safety of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis
Important dates
- Study start
- 2002
- First posted
- Nov 14, 2002
- Registry last updated
- Aug 15, 2006
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Dietary Salt in Rheumatoid Arthritis
NCT03649178
Arthritis, Arthritis, Rheumatoid
Nashville, Tennessee, United States
View Trial DetailsLong Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis
NCT03025308
Arthritis, Arthritis, Rheumatoid
Huntsville, Alabama, United States
View Trial DetailsUmbilical Cord Mesenchymal Stromal Cell Secretome for Moderate Rheumatoid Arthritis: A Randomized Double-Blind Placebo-Controlled Trial
NCT07715045
Arthritis, Arthritis, Rheumatoid
Palembang, South Sumatera, Indonesia
View Trial DetailsStudy of Families With Twins or Siblings Discordant for Rheumatic Disorders
NCT00055055
Arthritis, Arthritis, Rheumatoid
Bethesda, Maryland, United States
View Trial Details